CTO Intervention via PCI Leads to Better Symptom Relief and Quality of Life

A new meta‑analysis published in JACC provides strong evidence that percutaneous coronary intervention (PCI) for a chronic total occlusion (CTO) significantly improves symptoms, functional capacity, and quality of life compared with optimal medical therapy (OMT) alone. By focusing exclusively on patients with a single CTO lesion, the analysis resolves longstanding uncertainty created by earlier trials with mixed designs and confounding from multivessel disease.

Why This Matters

CTO lesions are present in 15–20% of patients with chronic coronary syndrome, yet guideline recommendations for CTO PCI remain cautious. This hesitancy reflects:

• Variability in earlier trial designs

• Lower historical procedural success rates

• Higher complication risks

• Confounding from non‑CTO PCI in medical‑therapy arms of prior studies

The new meta‑analysis eliminates these issues by isolating patients with one CTO and no other significant coronary lesions, allowing a clearer assessment of the true therapeutic benefit of CTO PCI.

Key Findings From the Meta‑Analysis

The combined dataset included 518 patients with stable angina and a single CTO. Across all domains of the Seattle Angina Questionnaire (SAQ)—including angina frequency, physical limitation, and quality of life—patients treated with CTO PCI experienced significantly greater improvements than those treated with OMT.

Additional highlights:

• Benefits were consistent across age, sex, diabetes status, and lesion complexity

• Patients with more severe baseline symptoms experienced the largest improvements

• Procedural success exceeded 92% after a second attempt

• Long‑term safety outcomes were similar between PCI and OMT

• OMT‑treated patients were more likely to require subsequent revascularization

These findings align with earlier evidence from the ORBITA‑CTO, EUROCTO, and DECISION‑CTO trials.

Meta‑Analysis Summary Table

Included Trials and Key Characteristics

Trial	Design	Population Included	Key Features	Original Findings
EUROCTO	Randomized	272 patients with single CTO	Compared CTO PCI vs OMT	PCI improved angina, physical limitations, and quality of life
DECISION‑CTO	Randomized	246 patients with single CTO (multivessel disease excluded for this analysis)	Original design allowed PCI of non‑CTO lesions	No difference between PCI and OMT due to cross‑over PCI in OMT arm

Meta‑Analysis Findings (518 Patients)

Outcome	PCI Group	OMT Group	Key Takeaway
Angina Frequency (SAQ)	Significant improvement	Less improvement	PCI provides superior angina relief
Quality of Life (SAQ QoL)	Significant improvement	Less improvement	PCI leads to better QoL gains
Physical Limitation (SAQ PL)	Improved (P < 0.01)	Less improvement	PCI improves functional capacity
SAQ Summary Score	Larger improvement	Smaller improvement	Overall health status benefit
Clinically meaningful improvement	More patients met thresholds	Fewer met thresholds	PCI more likely to produce clinically important changes
CTO PCI Success Rate	88.7% first attempt; 92.2% after second	N/A	High procedural success
Cross‑over to PCI	N/A	6.7%	Some OMT patients required PCI
Complications	Low (1% non‑Q‑wave MI; 0.7% silent cerebral ischemia)	N/A	Acceptable safety profile
Long‑term outcomes (3.1 years)	Cardiac death or nonfatal MI: 2.7%	5.1%	No significant difference
Revascularization	Lower	Higher	OMT patients more likely to need later PCI

Guideline Implications

Current US guidelines assign CTO PCI a class IIb recommendation, while European guidelines provide a class IIa recommendation for patients with persistent angina despite OMT. The new findings suggest:

• CTO PCI is effective

• CTO PCI is safe

• CTO PCI provides meaningful improvements in daily functioning and symptom burden

However, CTO PCI remains a technically demanding procedure, and outcomes depend heavily on operator experience, which likely explains the continued caution in guideline language.

Looking Ahead

Further clarity is expected from the ongoing ISCHEMIA‑CTO trial, which is evaluating PCI versus OMT in patients with varying degrees of ischemia, including those without symptoms. Results are anticipated in the coming years.

For now, the evidence is converging: In patients with a single CTO and persistent symptoms, PCI offers substantial improvements in quality of life, physical function, and angina relief.

Multifaceted Intervention Controls BP in Low‑income Hypertension Patients

 A new analysis from the IMPACTS‑BP trial shows that intensive blood pressure (BP) control is achievable even in resource‑limited primary‑care settings in the United States. Conducted across federally qualified health centers (FQHCs) in Louisiana and Mississippi, the study demonstrated that a systematic, team‑based intervention can significantly reduce systolic BP among low‑income adults.

A Real‑World Strategy With Real Impact

The intervention combined several coordinated components:

• Protocol‑driven medication management
• Team‑based care with regular auditing
• Health coaching
• Home BP monitoring

Among the 1,272 adults enrolled—most earning under $25,000 annually—those receiving the multifaceted intervention achieved a 6.4 mm Hg greater reduction in systolic BP at 18 months compared with usual care. Even modest reductions of this size are associated with meaningful decreases in long‑term cardiovascular risk, including stroke, coronary disease, heart failure, and mortality.

Nearly 22% of patients in the intervention arm reached a systolic BP below 120 mm Hg, and almost 48% achieved levels below 130 mm Hg—demonstrating that intensive BP targets can be met outside controlled research environments.

Why This Matters

Hypertension remains one of the most common and undertreated conditions in the United States, with low‑income communities facing disproportionate burdens. The IMPACTS‑BP findings show that structured, scalable care models can help close this gap.

While the results did not fully match the dramatic BP reductions seen in the landmark SPRINT trial, the comparison is limited by differences in setting. SPRINT operated under tightly controlled conditions, whereas IMPACTS‑BP took place in busy clinics serving patients with significant social and economic challenges. The fact that the intervention still produced substantial improvements underscores its real‑world value.

Looking Ahead

Experts agree that the next step is broader implementation. Success will require:

• Policy support and reimbursement pathways for health coaching and home monitoring
• System‑level commitment to team‑based care
• Ensuring affordable access to antihypertensive medications

If scaled effectively, the IMPACTS‑BP model could transform hypertension control in underserved communities and bring intensive BP management into everyday practice.

---

References & Further Reading

• Multifaceted strategies for hypertension control in low‑income patients. New England Journal of Medicine, 2026.
  https://www.nejm.org
• SPRINT Research Group. A randomized trial of intensive versus standard blood‑pressure control. New England Journal of Medicine, 2015.
  https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 (nejm.org in Bing)
• TCTMD Coverage of IMPACTS‑BP Trial
  https://www.tctmd.com

Beyond Quality of Life: Is TTVR Finally Moving the Needle on Mortality?

For years, the conversation around transcatheter tricuspid valve replacement (TTVR) has been defined by a significant caveat: we can make patients feel better, but can we help them live longer? Data from the TRISCEND II trial, recently presented at ACC 2026, suggests the tide may be turning.

While initial approvals for devices like Evoque were rooted in dramatic improvements in health status and KCCQ scores, the 2-year data now offers "provocative" hints of a survival benefit.

The 2-Year Snapshot: TRISCEND II

The trial randomized patients with symptomatic, severe tricuspid regurgitation (TR) to TTVR plus optimal medical therapy (OMT) versus OMT alone.

• TR Reduction: The efficacy remains undisputed. At 2 years, approximately 95% of TTVR and crossover patients maintained TR grades of mild or less.

• The Mortality Signal: In a landmark analysis at one year, patients who did not cross over to TTVR had a significantly higher rate of all-cause mortality (44.9%) compared to those in the TTVR group (19.1%).

• Quality of Life: The KCCQ-OS improvement was sustained, showing a nearly 18-point jump in the TTVR group compared to negligible gains in the OMT-only cohort.

The "Pacemaker" Problem

It wasn't all clear skies. The data highlighted a cumulative pacemaker rate of 19.7% in the TTVR cohort at 2 years, compared to just 9.0% in the control group. For the "forgotten valve," the price of a dry annulus often remains a conduction disturbance—a factor that remains a critical part of the heart team discussion.

Clinical Takeaway

We are moving from a "symptom-relief" mindset to a "disease-modifying" one. While these 2-year results are hypothesis-generating due to small sample sizes and high crossover rates, they reinforce a fundamental surgical truth: TR is not a benign bystander. As we refine patient selection, the choice between repair and replacement will increasingly hinge on balancing the immediate safety of edge-to-edge repair against the definitive (and potentially life-extending) TR elimination provided by replacement.

---

What are your thoughts on the 20% pacemaker risk? Is it a fair trade for a 25% absolute reduction in mortality?

Article inspired by recent findings presented at the American College of Cardiology 2026 Scientific Session.

Lipoprotein(a): Why This Inherited Lipid Matters in Cardiovascular Prevention

Lipoprotein(a), or Lp(a), is an inherited, largely stable lipid particle that can increase cardiovascular risk beyond what is captured by a standard lipid panel. 

In modern preventive cardiology, it is best viewed as a risk-enhancing factor that can help refine treatment decisions, especially in patients with premature or unexplained ASCVD.

What Lp(a) is

Lp(a) is structurally similar to LDL but contains an added apolipoprotein(a) component attached to apoB-100. This unique structure appears to contribute to atherogenic, inflammatory, and possibly prothrombotic effects. 

Unlike LDL-C, Lp(a) is determined mainly by genetics and is usually established early in life, remaining relatively constant over time.

Why it matters

Elevated Lp(a) is associated with myocardial infarction, stroke, peripheral arterial disease, and calcific aortic valve disease. 

Risk becomes especially relevant when Lp(a) is elevated in a patient who otherwise appears to have acceptable LDL-C control. 

In that setting, Lp(a) may explain residual risk and support a more intensive prevention strategy.

Who should be tested

Lp(a) measurement is particularly useful in patients with a family history of premature ASCVD, personal premature ASCVD, familial hypercholesterolemia, or a family history of elevated Lp(a). 

The 2026 ACC/AHA Dyslipidemia Guideline strongly recommends universal screening of adults for elevated Lp(a), with special considerations for children under 18. 

Because levels are generally stable, repeat testing is usually not needed unless there is a specific clinical reason.

How to interpret results

A commonly used threshold for elevated Lp(a) is 125 nmol/L, or 50 mg/dL. 

At or above this level, Lp(a) is considered a cardiovascular risk-enhancing factor. 

The key clinical point is not just the number itself, but how it changes overall risk assessment and treatment intensity.

Current management

There is no widely approved, outcome-proven therapy that specifically eliminates Lp(a) risk. 

Therefore, management focuses on aggressive control of modifiable factors, especially LDL-C reduction, blood pressure control, diabetes management, weight optimization, and tobacco cessation.

  Statins remain foundational for ASCVD prevention, even though they do not lower Lp(a), and PCSK9 inhibitors may modestly reduce Lp(a) while improving overall risk.

Emerging therapies

The field is moving quickly. Several RNA-targeting therapies are in late-stage clinical trials, including pelacarsen, olpasiran, and lepodisiran, with additional agents such as zerlasiran and muvalaplin in development. 

These studies are important because they may finally answer the central question: does directly lowering Lp(a) reduce cardiovascular events?

Clinical takeaway

Lp(a) should be treated as a marker of inherited risk, not a curiosity on a lipid report. 

For patients with elevated Lp(a), the practical response is to intensify overall cardiovascular prevention and use shared decision-making to explain why the risk is higher even when LDL-C looks controlled. 

That approach helps personalize care while we await definitive outcome data for Lp(a)-specific therapies.

References

1. American Heart Association. Lipoprotein(a) information pageAHA-Lpa-Toolkit.pdf

2. American Heart Association. Cholesterol overviewAHA-Lpa-Toolkit.pdf

3. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423ahajournals

4. National Lipid Association. 2026 ACC/AHA Multisociety Dyslipidemia Guideline Releasedlipid

5. Reyes-Soffer G, et al. Lp(a) AHA Scientific StatementAHA-Lpa-Toolkit.pdf

6. Wilson DP, et al. NLA Statement on Lp(a)AHA-Lpa-Toolkit.pdf

A $50 Million Unstable Angina Case

A recent $50 million wrongful‑death verdict in Alabama centers on a scenario familiar to cardiologists: a symptomatic patient with high‑risk unstable angina, a significant coronary lesion documented on catheterization, and a decision to discharge rather than admit and treat. Expert testimony suggested that with standard inpatient management and antithrombotic therapy, the patient’s likelihood of survival would have been extremely high, underscoring how preventable this outcome likely was.

High‑risk unstable angina within the NSTE‑ACS spectrum

Clinically, this case fits high‑risk unstable angina within the non‑ST‑elevation acute coronary syndrome (NSTE‑ACS) spectrum: days of chest and interscapular pain, exertional symptoms, and an angiographically significant coronary lesion, without any description of ST‑segment elevation. Current ESC and ACC/AHA guidance manage high‑risk unstable angina and NSTEMI similarly, emphasizing admission, antithrombotic therapy, and an early invasive strategy in patients with ongoing ischemia or high‑risk features.

The 2020 ESC NSTE‑ACS guidelines, for example, recommend an early invasive strategy (within 24 hours) for patients with high‑risk features such as dynamic ST‑T changes, elevated troponin, GRACE score >140, or ongoing/recurrent ischemia. A symptomatic patient with a clearly significant coronary lesion on cath almost certainly meets a high‑risk threshold and is difficult to justify as a routine same‑day discharge.

The post‑cath inflection point

The critical clinical decision was what happened after the significant lesion was documented on catheterization. In a patient with high‑risk unstable angina, guideline‑concordant care typically involves inpatient monitoring, dual antiplatelet therapy, parenteral anticoagulation, and timely revascularization within an early invasive strategy framework.

Instead, the patient was discharged, cleared for an imminent elective eye surgery, and reportedly advised to defer starting blood thinners until after that procedure. That sequence effectively prioritized a noncardiac elective operation over stabilizing an unstable coronary substrate, which is difficult to reconcile with ACS guidance that places immediate ischemic risk above nonurgent surgery.

How protocol drift creeps in

Several elements of protocol drift are recognizable in this case.

• Persistent chest and back pain with dyspnea over several days was not consistently treated as ongoing ischemia in a high‑risk unstable angina framework.

• Scheduling pressure around an elective ophthalmologic procedure appears to have influenced decision‑making more than the near‑term risk of myocardial infarction or sudden death.

• Post‑cath disposition seems to have occurred outside a structured NSTE‑ACS pathway that would default to admission and early invasive management for high‑risk unstable angina.

Both ESC and ACC/AHA guidance stress that high‑risk NSTE‑ACS, including high‑risk unstable angina, should not be managed as “stable” disease. These patients carry substantial short‑term event risk and are expected to remain hospitalized until adequately treated.

Documentation, guidelines, and credibility

From a medicolegal standpoint, the case also underscores the centrality of contemporaneous documentation. The jury appears to have relied heavily on the clinic’s own records, including the cardiologist’s notes describing symptoms, findings, and the discharge plan. The defense position required challenging or re‑interpreting those same records, which jurors understandably perceived as undermining credibility rather than clarifying nuance.

When management deviates from what ACS guidelines and institutional pathways would predict—such as discharging a patient with high‑risk unstable angina and a significant lesion—the rationale must be explicitly documented: diagnostic uncertainty, specific patient preferences, procedural constraints, or competing risks. Without that, any attempt to reconstruct the reasoning later risks sounding like litigation‑driven revisionism rather than real‑time clinical judgment.

Practical takeaways for cardiology teams

For cardiologists, fellows, and service leaders, this case is a prompt to stress‑test local ACS processes:

• Ensure NSTE‑ACS/unstable angina pathways clearly define high‑risk criteria and strongly default to admission, antithrombotic therapy, and early invasive management when they are present.

• Treat post‑cath disposition for high‑risk unstable angina as a high‑stakes decision point, not a routine checkbox; any decision to discharge should be an exception with clear documentation.

• Make explicit that noncardiac elective procedures never supersede short‑term ACS risk—when in doubt, delay the eye surgery, not the ACS management.

• Teach trainees that adherence to Class I recommendations for high‑risk NSTE‑ACS (including high‑risk unstable angina) is both a patient‑safety and risk‑management strategy, improving outcomes and making care easier to defend if later scrutinized.

Cases like this are devastating for families and emotionally taxing for clinicians. The constructive response is not to practice reflexively defensive medicine, but to tighten our alignment between risk recognition, guideline‑based unstable angina care, and what actually happens at the bedside.

References

1. MDLinx. “$50 million for cardiology protocol failure: Where did the decision-making break down?” March 23, 2026.[mdlinx]

2. Collet J‑P, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation. Eur Heart J. 2021;42(14):1289‑1367.[academic.oup +2]

3. ESC Council for Cardiology Practice. “2020 ESC NSTE‑ACS Guidelines: Key Points.” European Society of Cardiology website.[acc +1]

4. ACC/AHA/ACEP/NAEMSP/SCAI Guideline‑related resources on ACS and NSTE‑ACS. American Heart Association / American College of Cardiology professional pages.[ahajournals +1]

5. LITFL. “NSTEACS Management.” Critical Care Compendium.[litfl]

The Ultimate Stress Test: Artemis II Through a Cardiologist’s Lens

As the world watches the Artemis II mission prepare to carry four astronauts around the Moon, most eyes are on the trajectory and the tech. But as a cardiologist, I’m looking at a different set of instruments: the four human hearts beating inside the Orion spacecraft.

For the first time in over 50 years, humans are leaving the protective "bubble" of Low Earth Orbit (LEO). This isn't just a leap for exploration; it’s the ultimate cardiovascular stress test. Here is how deep space challenges the most vital muscle in the body.

1. The Great Fluid Shift: "Puffy Head, Bird Legs"

In Earth’s gravity, our cardiovascular system works tirelessly to pump blood upward against gravity. The moment the Artemis II crew hits microgravity, that workload vanishes.

Without gravity to pull fluids down, blood and interstitial fluid migrate toward the chest and head. This cephalad fluid shift creates what we call the "puffy face, bird legs" look. For a cardiologist, this is a fascinating acute volume overload scenario. The heart initially perceives this as "too much fluid" and responds by increasing stroke volume, but over time, the body adjusts by reducing overall plasma volume by about 10% to 15%.

2. Cardiac Atrophy: Use It or Lose It

The heart is a muscle, and like any muscle, it adapts to its workload. In space, the heart doesn't have to work as hard to circulate blood. Research from the International Space Station has shown that the heart can actually change shape, becoming more spherical and losing muscle mass (atrophy) during extended missions.

While Artemis II is a relatively short 10-day mission, it serves as a critical baseline for the longer lunar stays to come. We are watching to see how the heart handles the rapid transition from the high-G forces of launch to the "lazy" pumping requirements of deep space.

3. The Wild Card: Deep Space Radiation

This is where Artemis II differs from missions to the ISS. Once the crew leaves the Van Allen radiation belts, they are exposed to Galactic Cosmic Rays (GCRs) and solar particle events.

From a clinical perspective, space radiation is a known "accelerator" of cardiovascular aging. It can damage the endothelial lining of blood vessels, potentially speeding up atherosclerosis (hardening of the arteries) and causing oxidative stress. Artemis II is a vital data-gathering mission to help us understand how to protect future Mars-bound travelers from radiation-induced heart disease.

4. Heart Health on a Chip

One of the most exciting aspects of this mission is the AVATAR (A Virtual Astronaut Tissue Analog Response) investigation. NASA is using "organ-on-a-chip" technology—essentially tiny 3D cultures of the astronauts' own cells—to monitor how their specific heart tissue reacts to the unique stressors of deep space in real-time.

> Cardiologist’s Note: This isn't just for space. Understanding how hearts "age" or stiffen in microgravity helps us treat sedentary patients and those with heart failure right here on Earth.

> 

The Return: Orthostatic Intolerance

The mission doesn't end when the capsule splashes down. When the crew returns to Earth’s 1G environment, gravity immediately pulls that blood back down to their legs. Because their hearts have spent 10 days "slacking off" and their blood volume is lower, many astronauts experience orthostatic intolerance—the inability to stand without feeling faint.

Final Thoughts

Artemis II is more than a lunar flyby; it’s a clinical trial for the future of humanity. As we push further into the cosmos, our understanding of the heart must evolve. We aren't just sending pilots and scientists to the Moon; we are sending the most complex, adaptive, and vulnerable biological pump ever designed.

Stay tuned as we follow the vitals of the Artemis II crew. The heartbeat of exploration has never been louder.

For more updates on the intersection of medicine and space, visit NASA’s Human Research Program.